# EVFM catalysts: Evofem Biosciences, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/evfm/catalysts

> Evofem Biosciences, Inc. (EVFM) has no upcoming catalysts in this calendar. The latest recorded is the Evofem Biosciences, Inc. earnings report, November 13, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Evofem Biosciences, Inc. |
| Ticker | EVFM (OTC) |
| SEC CIK | 1618835 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/evfm |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 28, 2016 | [Phexx (citric acid; lactic acid; potassium bitartrate) complete response letter (CRL)](https://sec-api.dev/pdufa/citric-acid-lactic-acid) | EVFM |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22208352_2020_Orig1s000OtherActionLtrs.pdf%22)) |
| September 15, 2017 | [Solosec (secnidazole) FDA approval](https://sec-api.dev/pdufa/secnidazole) | EVFM |  | completed, approved | "NDA209363 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170915, review_priority PRIORITY; sponsor_name EVOFEM INC; product SOLOSEC (SECNIDAZOLE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209363%22)) |
| May 22, 2020 | [Phexx (citric acid; lactic acid; potassium bitartrate) FDA approval](https://sec-api.dev/pdufa/citric-acid-lactic-acid) | EVFM |  | completed, approved | "NDA208352 ORIG-1 (Type 3 - New Dosage Form and Type 4 - New Combination): submission_status AP, submission_status_date 20200522, review_priority STANDARD; sponsor_name EVOFEM INC; product PHEXX (CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208352%22)) |
| June 30, 2021 | [Solosec (secnidazole) label expansion decision](https://sec-api.dev/pdufa/secnidazole) | EVFM |  | completed, approved | "NDA209363 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20210630, review_priority STANDARD; sponsor_name EVOFEM INC; product SOLOSEC (SECNIDAZOLE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209363%22)) |
| January 26, 2022 | [Solosec (secnidazole) label expansion decision](https://sec-api.dev/pdufa/secnidazole) | EVFM |  | completed, approved | "NDA209363 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20220126, review_priority STANDARD; sponsor_name EVOFEM INC; product SOLOSEC (SECNIDAZOLE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209363%22)) |
| November 14, 2024 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "Biosciences Announces Financial Results for the Third Quarter of 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000149315224046043/ex99-1.htm)) |
| March 24, 2025 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "DIEGO, CA, March 24, 2025 — Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000164117225000209/ex99-1.htm)) |
| May 15, 2025 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "Reports First Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000164117225010526/ex99-1.htm)) |
| August 14, 2025 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000164117225023740/ex99-1.htm)) |
| November 13, 2025 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "Reports Financial Results for Third Quarter of 2025, Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/ex99-1.htm)) |
| March 11, 2026 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "DIEGO, CA, March 11, 2026 — Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000149315226009689/ex99-1.htm)) |
| May 18, 2026 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000149315226024095/ex99-1.htm)) |
| November 13, 2026 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000149315226051806/ex99-1.htm)) |

## Drugs

- [Phexx (citric acid; lactic acid; potassium bitartrate)](https://sec-api.dev/pdufa/citric-acid-lactic-acid): 
- [Solosec (secnidazole)](https://sec-api.dev/pdufa/secnidazole): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/evfm/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "EVFM catalysts: Evofem Biosciences, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/evfm/catalysts

```bibtex
@misc{secapidev_companies_evfm_catalysts_20261116,
  title        = {EVFM catalysts: Evofem Biosciences, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/evfm/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_evfm_catalysts_20261116","title":"EVFM catalysts: Evofem Biosciences, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/evfm/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
